Lantern Pharma Inc (LTRN)

12:14 PM

IBM Accelerates Enterprise Gen AI Revolution With Hybrid Capabilities - Barchart.com

12:14 PM

May 05, 2025

Soybeans Fall To Start The Week - Barchart.com

May 05, 2025

May 05, 2025

Lucintel Forecasts The Global MRD Testing Market To Reach $3.4 Billion By 2031 - Barchart.com

May 05, 2025

May 05, 2025

Wellesley Homes Get A Touch Of Glam With IDEAL Showers - Barchart.com

May 05, 2025

May 05, 2025

Powersolv, Inc. Announces Headquarters Relocation To Montgomery County, Maryland - Barchart.com

May 05, 2025

May 05, 2025

Recovery Support In Muskoka: A Closer Look At Rehabilitation Services In Ontario - Barchart.com

May 05, 2025

May 05, 2025

Wheat Posting Monday Losses - Barchart.com

May 05, 2025

May 05, 2025

Lantern Pharma (LTRN) Gets FDA Green Light to Begin Human Trials for New Breast Cancer Drug - Barchart.com

May 05, 2025

May 05, 2025

The Stonegate Firm Achieves Full BBB Accreditation And Maintains An A+ Rating - Barchart.com

May 05, 2025

May 05, 2025

Lantern Pharma (LTRN) Gains FDA Approval for Clinical Trial in Breast Cancer | LTRN Stock News - GuruFocus

May 05, 2025

May 05, 2025

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) | LTRN Stock News - GuruFocus

May 05, 2025

May 05, 2025

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) - Business Wire

May 05, 2025

May 05, 2025

Lantern Pharma Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView

May 05, 2025

May 01, 2025

RCMP In Eastern Newfoundland Take Over Search For Pilot Of Downed Small Plane - Barchart.com

May 01, 2025

May 01, 2025

Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday - Defense World

May 01, 2025

May 01, 2025

What You Need To Know Ahead Of McCormick & Company's Earnings Release - Barchart.com

May 01, 2025

Apr 30, 2025

This Company Extended Its Post-Earnings Rally To Record Highs - Barchart.com

Apr 30, 2025

Apr 29, 2025

Major Companies Face A Difficult Task In Estimating The Impact Of Tariffs On Their Business - Barchart.com

Apr 29, 2025

Apr 29, 2025

New Advances In Healthcare AI Could Unlock Billions In Market Opportunity - Barchart.com

Apr 29, 2025

Apr 29, 2025

Wheat Buying The Fact Early On Tuesday Following Rating Improvement - Barchart.com

Apr 29, 2025

Apr 28, 2025

Hogs Facing Midday Weakness - Barchart.com

Apr 28, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 21, 2025

Cotton Closes With Weakness On Monday - Barchart.com

Apr 21, 2025

Apr 08, 2025

Lantern Pharma stock hits 52-week low at $2.77 amid market challenges - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

Lantern Pharma stock hits 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 06, 2025

Lantern Pharma : Announces Upcoming Conference Presentations - MarketScreener

Apr 06, 2025

Apr 05, 2025

Lantern Pharma (NASDAQ:LTRN) Research Coverage Started at Lake Street Capital - The AM Reporter

Apr 05, 2025

Apr 04, 2025

Lake Street Capital Begins Coverage on Lantern Pharma (NASDAQ:LTRN) - Defense World

Apr 04, 2025

Apr 02, 2025

Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - Nasdaq

Apr 02, 2025

Apr 02, 2025

Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance

Apr 02, 2025

Apr 02, 2025

Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navi - GuruFocus

Apr 02, 2025

Apr 02, 2025

Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada

Apr 02, 2025

Mar 30, 2025

Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials - MSN

Mar 30, 2025

Mar 29, 2025

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 28, 2025

Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges - TipRanks

Mar 28, 2025

Mar 28, 2025

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - BioSpace

Mar 28, 2025

Mar 28, 2025

Lantern Pharma Advances AI-Driven Oncology Pipeline - TipRanks

Mar 28, 2025

Mar 27, 2025

LANTERN PHARMA Earnings Results: $LTRN Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses - Investing.com India

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Inc (LTRN) Reports Q4 EPS of -$0.51, Aligning wit - GuruFocus

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Inc Qtrly EPS $-0.54 - MarketScreener

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Reports Q4 2024 Financial Results and AI Progress - TipRanks

Mar 27, 2025

Mar 26, 2025

Preview: Lantern Pharma's Earnings - Benzinga

Mar 26, 2025

Mar 25, 2025

Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Mar 25, 2025

Mar 20, 2025

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace

Mar 20, 2025

Mar 20, 2025

Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - Stock Titan

Mar 20, 2025

Mar 10, 2025

LTRN: M&A Illuminates GBM Value - Yahoo Finance

Mar 10, 2025

Mar 10, 2025

Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 10, 2025

Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World

Mar 10, 2025